ChemoCentryx, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022015596 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $328.6M $340.6M
YoY Change 5.12% -9.48%
Cash & Equivalents $44.40M $40.58M
Short-Term Investments $284.2M $300.0M
Other Short-Term Assets $6.137M $5.324M
YoY Change 40.82% 26.76%
Inventory $5.474M $2.897M
Prepaid Expenses
Receivables $4.946M $2.810M
Other Receivables $0.00 $0.00
Total Short-Term Assets $345.2M $351.6M
YoY Change 8.84% -9.98%
LONG-TERM ASSETS
Property, Plant & Equipment $30.86M $31.48M
YoY Change -47.77% -46.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.55M $31.24M
YoY Change -80.5% -34.79%
Other Assets $1.452M $1.512M
YoY Change 0.9% 0.8%
Total Long-Term Assets $74.22M $88.82M
YoY Change -50.7% -18.14%
TOTAL ASSETS
Total Short-Term Assets $345.2M $351.6M
Total Long-Term Assets $74.22M $88.82M
Total Assets $419.4M $440.5M
YoY Change -10.32% -11.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.592M $5.423M
YoY Change -31.57% -50.25%
Accrued Expenses $27.74M $25.55M
YoY Change 34.12% 20.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $19.72M $19.13M
YoY Change 51.88% 99.06%
Total Short-Term Liabilities $76.08M $68.81M
YoY Change 37.38% 25.79%
LONG-TERM LIABILITIES
Long-Term Debt $4.005M $4.554M
YoY Change -65.37% -69.37%
Other Long-Term Liabilities $235.0K $217.0K
YoY Change -99.67% -99.68%
Total Long-Term Liabilities $4.240M $4.771M
YoY Change -63.34% -67.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $76.08M $68.81M
Total Long-Term Liabilities $4.240M $4.771M
Total Liabilities $182.9M $181.7M
YoY Change 33.08% 31.6%
SHAREHOLDERS EQUITY
Retained Earnings -$687.4M -$655.7M
YoY Change
Common Stock $926.2M $916.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $236.5M $258.7M
YoY Change
Total Liabilities & Shareholders Equity $419.4M $440.5M
YoY Change -10.32% -11.75%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001340652
CY2021Q4 ccxi Commercial Manufacturing Related
CommercialManufacturingRelated
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35420
dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3254365
dei Entity Address Address Line1
EntityAddressAddressLine1
835 Industrial Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
San Carlos
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94070
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
210-2900
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71355872
dei Trading Symbol
TradingSymbol
CCXI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1452000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44396000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49978000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
284219000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
214514000
CY2022Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
4759000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
411000
CY2022Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
187000
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
43000
CY2022Q2 us-gaap Inventory Net
InventoryNet
5474000
CY2021Q4 us-gaap Inventory Net
InventoryNet
851000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6137000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3380000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
345172000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
269177000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30856000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32269000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
17551000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
97856000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24359000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24806000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1544000
CY2022Q2 us-gaap Assets
Assets
419390000
CY2021Q4 us-gaap Assets
Assets
425652000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7592000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6746000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27744000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26358000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
19720000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
18920000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21022000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10993000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
76078000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
63017000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4005000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4715000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
57299000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
24772000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45243000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46830000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
235000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
198000
CY2022Q2 us-gaap Liabilities
Liabilities
182860000
CY2021Q4 us-gaap Liabilities
Liabilities
139532000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1804000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 ccxi Product Sales Net
ProductSalesNet
0
ccxi Product Sales Net
ProductSalesNet
14446000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
ccxi Product Sales Net
ProductSalesNet
0
CY2022Q2 ccxi Product Supply Sales To Related Party
ProductSupplySalesToRelatedParty
866000
CY2021Q2 ccxi Product Supply Sales To Related Party
ProductSupplySalesToRelatedParty
0
CY2022Q2 ccxi Cost Of Sales
CostOfSales
803000
CY2021Q2 ccxi Cost Of Sales
CostOfSales
0
ccxi Product Supply Sales To Related Party
ProductSupplySalesToRelatedParty
866000
ccxi Product Supply Sales To Related Party
ProductSupplySalesToRelatedParty
0
ccxi Cost Of Sales
CostOfSales
1008000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71344838
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71344838
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70357557
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70357557
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
71000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
70000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
926141000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
903646000
CY2022Q2 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2021Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2310000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-483000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-687356000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-617097000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
236530000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
286120000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
419390000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
425652000
CY2022Q2 ccxi Product Sales Net
ProductSalesNet
9093000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1699000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1910000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
11922000
CY2022Q2 ccxi Grant Revenue
GrantRevenue
0
CY2021Q2 ccxi Grant Revenue
GrantRevenue
114000
ccxi Grant Revenue
GrantRevenue
0
ccxi Grant Revenue
GrantRevenue
244000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11763000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1813000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17222000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12166000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38738000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1827000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-195000
ccxi Cost Of Sales
CostOfSales
0
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14355000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20853000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31831000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44271000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28179000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19698000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54190000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35960000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
43337000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
40551000
us-gaap Costs And Expenses
CostsAndExpenses
87029000
us-gaap Costs And Expenses
CostsAndExpenses
80231000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31574000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69807000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68065000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
509000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
224000
us-gaap Investment Income Interest
InvestmentIncomeInterest
731000
us-gaap Investment Income Interest
InvestmentIncomeInterest
529000
CY2022Q2 us-gaap Interest Expense
InterestExpense
586000
CY2021Q2 us-gaap Interest Expense
InterestExpense
695000
us-gaap Interest Expense
InterestExpense
1183000
us-gaap Interest Expense
InterestExpense
1384000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-471000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-452000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-855000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31651000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-39209000
us-gaap Net Income Loss
NetIncomeLoss
-70259000
us-gaap Net Income Loss
NetIncomeLoss
-68920000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71234
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69788
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71035
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69698
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31651000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-39209000
us-gaap Net Income Loss
NetIncomeLoss
-70259000
us-gaap Net Income Loss
NetIncomeLoss
-68920000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-455000
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-67000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17054000
ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
507000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32106000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39276000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72086000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
236530000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
361004000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69115000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258719000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31651000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-39209000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-19000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-455000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1782000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7872000
CY2022Q2 ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
263000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
236530000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
286120000
us-gaap Net Income Loss
NetIncomeLoss
-70259000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1827000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8061000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3126000
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-67000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1099000
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
260000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7454000
CY2021Q2 ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
249000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
330270000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
385613000
us-gaap Net Income Loss
NetIncomeLoss
-68920000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-195000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3262000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5273000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15294000
ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
489000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
330270000
us-gaap Profit Loss
ProfitLoss
-70259000
us-gaap Profit Loss
ProfitLoss
-68920000
us-gaap Share Based Compensation
ShareBasedCompensation
17561000
us-gaap Share Based Compensation
ShareBasedCompensation
15783000
us-gaap Depreciation
Depreciation
2041000
us-gaap Depreciation
Depreciation
1120000
ccxi Non Cash Lease Expense
NonCashLeaseExpense
448000
ccxi Non Cash Lease Expense
NonCashLeaseExpense
1165000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1698000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1771000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
4348000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-19000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
144000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
21000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4623000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2891000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-994000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-92000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14177000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
126757000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
846000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2636000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
198944000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
134128000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
299555000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6743000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
ccxi Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1363000
ccxi Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
8094000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1091000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-214000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
42556000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1864000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17295000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39418000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
628000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
86434000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8096000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3165000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3126000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5273000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4970000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2108000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5582000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
44908000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51058000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33377000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45476000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78285000
us-gaap Interest Paid Net
InterestPaidNet
986000
us-gaap Interest Paid Net
InterestPaidNet
1029000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
455000
ccxi Purchases Of Property And Equipment Net Recorded In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentNetRecordedInAccountsPayableAndAccruedLiabilities
0
ccxi Purchases Of Property And Equipment Net Recorded In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentNetRecordedInAccountsPayableAndAccruedLiabilities
4436000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Description of Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a fully integrated United States biopharmaceutical company focused on the development and commercialization of new medications targeting inflammatory disorders, autoimmune diseases and cancer. The Company discovered, developed and is now commercializing TAVNEOS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Symbol;min-width:fit-content;">Ò</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (avacopan) in the U.S. as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids, and not for the elimination of glucocorticoids use. The Company’s principal operations are in the U.S. and it operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> segment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2021 Condensed Consolidated Balance Sheet was derived from audited financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> filed with the Securities and Exchange Commission on March 1, 2022.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2310000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
354330000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
41960000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
214514000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company invests in a variety of financial instruments and, by its policy, limits the amount of credit exposure with any one issuer, industry or geographic area.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For the three and six months ended June 30, 2022 and 2021, total revenue derived from the Company’s collaboration with Vifor (International) Ltd., and/or its affiliates, or collectively, Vifor, was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">93.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">98.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, respectively. Accounts receivable are typically unsecured and are concentrated within a few customers in the pharmaceutical industry and government sector. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies and government funded entities. The Company has not historically experienced any significant losses due to concentration of credit risk. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> customers represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's accounts receivable at June 30, 2022 and December 31, 2021, respectively, and each of these customers represented 10% or greater of the Company's accounts receivable. For each of the three and six months ended June 30, 2022, these </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">two</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> customers represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's product sales, net. The Company began commercializing TAVNEOS in the U.S. in October 2021 and had no product sales, net prior to October 2021.</span></p>
CY2022Q2 ccxi Contract Revenue Upfront Payment Earned As Percentage Of Revenue
ContractRevenueUpfrontPaymentEarnedAsPercentageOfRevenue
0.227
CY2021Q2 ccxi Contract Revenue Upfront Payment Earned As Percentage Of Revenue
ContractRevenueUpfrontPaymentEarnedAsPercentageOfRevenue
0.937
ccxi Contract Revenue Upfront Payment Earned As Percentage Of Revenue
ContractRevenueUpfrontPaymentEarnedAsPercentageOfRevenue
0.161
ccxi Contract Revenue Upfront Payment Earned As Percentage Of Revenue
ContractRevenueUpfrontPaymentEarnedAsPercentageOfRevenue
0.980
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7859
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7859
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8001
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8001
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
97856000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
354330000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
345802000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44396000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49978000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1080000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1080000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45476000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51058000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1390000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27744000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
343492000
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
41722000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
284219000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
17551000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
343492000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
354813000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
490000
CY2022Q2 us-gaap Cash
Cash
2700000
CY2021Q4 us-gaap Cash
Cash
8000000.0
ccxi Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
less than two years
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2022Q2 ccxi Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2022Q2 ccxi Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2022Q2 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
9539000
CY2021Q4 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
11309000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6737000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8350000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1329000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1348000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3035000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2810000
CY2022Q2 ccxi End Of Term Charge On The Long Term Debt
EndOfTermChargeOnTheLongTermDebt
1196000
CY2021Q4 ccxi End Of Term Charge On The Long Term Debt
EndOfTermChargeOnTheLongTermDebt
1151000
CY2022Q2 ccxi Commercial Manufacturing Related
CommercialManufacturingRelated
3013000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2895000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26358000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3035000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
20000000.0
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0805
CY2017Q4 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0805
CY2020Q1 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0850
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
23700000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
200000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
18951000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1979000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2566000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
455000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
23951000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
226000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
23725000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
19720000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4005000
CY2022Q2 us-gaap Contractual Obligation
ContractualObligation
11600000
CY2022Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
ccxi Lessee Operating Lease New Facility Commence Month And Year
LesseeOperatingLeaseNewFacilityCommenceMonthAndYear
June 2020
ccxi Expiration Date
ExpirationDate
2031-02
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option to extend the lease for five years
us-gaap Operating Lease Expense
OperatingLeaseExpense
6500000
ccxi Incremental Percentage Of Annual Lease Rent
IncrementalPercentageOfAnnualLeaseRent
0.03
ccxi Proceeds From Tenant Allowance
ProceedsFromTenantAllowance
15400000
ccxi Proceeds From Additional Tenant Allowance
ProceedsFromAdditionalTenantAllowance
4800000
CY2022Q2 ccxi Additional Tenant Allowance Repayment Interest Percentage
AdditionalTenantAllowanceRepaymentInterestPercentage
0.07
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
20200000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7952000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8170000
CY2022Q2 ccxi Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
36517000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
71598000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24359000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23320000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24806000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
48278000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2810000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45243000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46830000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1375000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1740000
us-gaap Operating Lease Cost
OperatingLeaseCost
2750000
us-gaap Operating Lease Cost
OperatingLeaseCost
3482000
us-gaap Operating Lease Payments
OperatingLeasePayments
4000000.0
us-gaap Operating Lease Payments
OperatingLeasePayments
2000000.0
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
0
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
7700000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3683000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7535000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7741000
CY2022Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
2254000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2016Q2 ccxi Upfront Payment Received
UpfrontPaymentReceived
78000000.0
CY2016Q2 ccxi Non Refundable Up Front Payment Received
NonRefundableUpFrontPaymentReceived
85000000.0
CY2016Q2 ccxi Non Refundable Upfront Payments Allocated For Issuance Of Common Stock
NonRefundableUpfrontPaymentsAllocatedForIssuanceOfCommonStock
7000000.0
CY2016Q2 ccxi Non Refundable Upfront Payment Received In Equity Investment Shares
NonRefundableUpfrontPaymentReceivedInEquityInvestmentShares
3333333
CY2016Q2 ccxi Non Refundable Upfront Payments Allocated For Issuance Of Common Stock Per Share Value
NonRefundableUpfrontPaymentsAllocatedForIssuanceOfCommonStockPerShareValue
2.10
CY2016Q2 ccxi Collaboration And License Agreements Transaction Price
CollaborationAndLicenseAgreementsTransactionPrice
78000000.0
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2483000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2483000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5641782
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6767895
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2098105
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1402398
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
27.94
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
693988
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.47
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Expired Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpiredOrForfeited
256874
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
256874
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
43.56
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3800551
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7219431
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y29D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72849218
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6904798
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y11M8D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
72382158
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4733359
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M29D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
67465870
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15400
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D

Files In Submission

Name View Source Status
0000950170-22-015596-index-headers.html Edgar Link pending
0000950170-22-015596-index.html Edgar Link pending
0000950170-22-015596.txt Edgar Link pending
0000950170-22-015596-xbrl.zip Edgar Link pending
ccxi-20220630.htm Edgar Link pending
ccxi-20220630.xsd Edgar Link pending
ccxi-ex31_1.htm Edgar Link pending
ccxi-ex31_2.htm Edgar Link pending
ccxi-ex32_1.htm Edgar Link pending
ccxi-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
ccxi-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ccxi-20220630_pre.xml Edgar Link unprocessable
ccxi-20220630_lab.xml Edgar Link unprocessable
ccxi-20220630_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ccxi-20220630_cal.xml Edgar Link unprocessable